Twist Bioscience Reports Strong Q3 Growth, Raises Full-Year Revenue Guidance
Twist Bioscience (NASDAQ:TWST) reported a strong performance in its fiscal third quarter with revenue rising 23% year over year to $118.4 million. The growth was driven by DNA Synthesis and Protein Solutions, which saw a 39% increase, as well as NGS Applications growing at 12%. Management raised full-year revenue guidance for fiscal 2026 to between $456 million and $457 million. The company highlighted AI-enabled drug discovery as an emerging growth engine. CEO Emily Leproust noted that demand is expanding, with customers increasingly using AI models in therapeutic design. Twist expects at least triple-digit order growth for fiscal 2026 and potentially again in 2027. Gross margin improved to 52.8%, and the company reiterated its goal of achieving adjusted EBITDA breakeven by Q4. Twist also launched a new product, Complex Genes, following strong early demand with over 1,800 constructs ordered during access trials.
Tickers: $TWST
Topics: ai drug discovery biotechnology dna synthesis ebitda breakeven